Multicenter Phase II Clinical Trial of Sorafenib Combined with TACE for Advanced Stage HCC (STAB Study)

PURPOSE To evaluate the safety and efficacy of combination therapy (TACE + sorafenib) in patients with advanced stage HCC. STUDY DESIGN Open-label, non-randomized, single-arm multicenter phase II clinical trial. The primary endpoint was defined as the rate of completion of the treatment protocol (i.e., 2 months duration of sorafenib following Read more…